# Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)

> **NCT01567813** · — · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 114035 (actual)

## Conditions studied

- Human Papilloma Virus Infection

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01567813
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-23
- **Primary completion:** 2019-06-01
- **Final completion:** 2019-06-01
- **Target enrollment:** 114035 (ACTUAL)
- **Last updated:** 2022-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01567813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01567813, "Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01567813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*